Surmodics Rolls Out Preside Hydrophilic Coatings

Surmodics has commercially launched its Preside hydrophilic coatings, which the company claims is its most advanced hydrophilic medical device coating technology.
 
Preside coatings complement the company’s Serene hydrophilic coatings with a low-friction, low-particulate generation coating to boost distal access for neurovascular applications. The company says the coatings can also improve crossing for challenging coronary lesions or chronic total occlusions.
 
Preside hydrophilic coatings are applied using Surmodics’ patented UV curing process, which covalently bonds surface treatments to substrates at ambient temperature. The company claims this flexible tech can easily be incorporated into existing manufacturing processes and can reduce production time and reagent costs compared to thermal-curing and alternative UV-based chemistries and processes.
 
Surmodics said the Preside coatings were specifically formulated to achieve the correct balance of enhanced lubricity and coating durability for the next generation of neurovascular, coronary, and peripheral vascular devices.
 
“Hydrophilic coatings are an essential feature to help medical devices access and navigate tortuous vascular pathways, allowing physicians to reach distal treatment sites for improved therapeutic outcomes,” Charlie Olson, senior VP and president of Surmodics’ Medical Device Coatings business, told the press. “We are pleased to secure the first 510(k) device clearance that leverages this new technology. Our Preside hydrophilic coatings strengthen our existing portfolio and sets a new performance standard for the industry, and the medical device manufacturers we serve.”
 
In June, the company’s SurVeil drug-coated balloon obtained U.S. Food and Drug Administration (FDA) approval.